Effective and Targeted Human Orthotopic Glioblastoma Xenograft Therapy via a Multifunctional Biomimetic Nanomedicine

© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 30(2018), 51 vom: 28. Dez., Seite e1803717
1. Verfasser: Zou, Yan (VerfasserIn)
Weitere Verfasser: Liu, Yanjie, Yang, Zhipeng, Zhang, Dongya, Lu, Yiqing, Zheng, Meng, Xue, Xue, Geng, Jia, Chung, Roger, Shi, Bingyang
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article biomimetic nanomedicine blood-brain-barrier chemotherapy glioblastoma multiforme multifunctional nanoparticles Angiopep-2 Peptides Doxorubicin 80168379AG
LEADER 01000caa a22002652 4500
001 NLM289628733
003 DE-627
005 20250224062320.0
007 cr uuu---uuuuu
008 231225s2018 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.201803717  |2 doi 
028 5 2 |a pubmed25n0965.xml 
035 |a (DE-627)NLM289628733 
035 |a (NLM)30328157 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Zou, Yan  |e verfasserin  |4 aut 
245 1 0 |a Effective and Targeted Human Orthotopic Glioblastoma Xenograft Therapy via a Multifunctional Biomimetic Nanomedicine 
264 1 |c 2018 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 25.03.2019 
500 |a Date Revised 20.04.2023 
500 |a published: Print-Electronic 
500 |a ErratumIn: Adv Mater. 2023 Apr;35(16):e2300776. doi: 10.1002/adma.202300776. - PMID 37078223 
500 |a Citation Status MEDLINE 
520 |a © 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. 
520 |a Glioblastoma multiforme (GBM) is a fatal central nervous system tumor without effective treatment. Chemotherapeutic agents are mainstays in the treatment of glioblastoma. However, the effectiveness of these is seriously hindered by poor blood-brain-barrier (BBB) penetrance and tumor targeting, together with short biological half-life. Improved chemotherapy is thus urgently needed for GBM. Multifunctional nanoparticle delivery systems offer much promise in overcoming current limitations. Accordingly, a multifunctional biomimetic nanomedicine is developed by functionalizing the surface of red blood cell membranes (RBCms) with angiopep-2 and loading pH-sensitive nanoparticles (polymer, doxorubicin (Dox), and lexiscan (Lex)) using the functionalized cell membrane to generate the novel nanomedicine, Ang-RBCmNM-(Dox/Lex). The studies toward orthotopic U87MG human glioblastoma tumor-bearing nude mice show that the Ang-RBCm@NM-(Dox/Lex) nanomedicine has much improved blood circulation time, superb BBB penetration, superior tumor accumulation and retention. Moreover, effective suppression of tumor growth and significantly improved medium survival time are also observed after Ang-RBCm@NM-(Dox/Lex) treatment. The results show that this biomimetic nanoplatform can serve as a flexible and powerful system for GBM treatment which can be readily adapted for the treatment of other central nervous system (CNS) disorders 
650 4 |a Journal Article 
650 4 |a biomimetic nanomedicine 
650 4 |a blood-brain-barrier 
650 4 |a chemotherapy 
650 4 |a glioblastoma multiforme 
650 4 |a multifunctional nanoparticles 
650 7 |a Angiopep-2  |2 NLM 
650 7 |a Peptides  |2 NLM 
650 7 |a Doxorubicin  |2 NLM 
650 7 |a 80168379AG  |2 NLM 
700 1 |a Liu, Yanjie  |e verfasserin  |4 aut 
700 1 |a Yang, Zhipeng  |e verfasserin  |4 aut 
700 1 |a Zhang, Dongya  |e verfasserin  |4 aut 
700 1 |a Lu, Yiqing  |e verfasserin  |4 aut 
700 1 |a Zheng, Meng  |e verfasserin  |4 aut 
700 1 |a Xue, Xue  |e verfasserin  |4 aut 
700 1 |a Geng, Jia  |e verfasserin  |4 aut 
700 1 |a Chung, Roger  |e verfasserin  |4 aut 
700 1 |a Shi, Bingyang  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 30(2018), 51 vom: 28. Dez., Seite e1803717  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnns 
773 1 8 |g volume:30  |g year:2018  |g number:51  |g day:28  |g month:12  |g pages:e1803717 
856 4 0 |u http://dx.doi.org/10.1002/adma.201803717  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 30  |j 2018  |e 51  |b 28  |c 12  |h e1803717